Fokale Therapie des Prostatakarzinoms

详细信息    查看全文

• 作者：Dr. D. Baumunk F.E.B.U (1)
  A. Blana (2)
  R. Ganzer (3)
  T. Henkel (4)
  J. K?llermann (5)
  A. Roosen (6)
  S. Machtens (7)
  G. Salomon (8)
  L. Sentker (9)
  U. Witzsch (10)
  K.U. K?hrmann (11)
  M. Schostak (1)
  
• 关键词：übersichtsarbeit ; Prostatakarzinom ; Fokale Therapie ; ?Active Surveillance-/li> Ablationsverfahren ; Review ; Prostate cancer ; Focal therapy ; Active surveillance ; Ablation therapies
• 刊名：Der Urologe A
• 出版年：2013
• 出版时间：April 2013
• 年：2013
• 卷：52
• 期：4
• 页码：549-556
• 全文大小：812 KB
• 参考文献：1. Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: progress and promise. J Clin Oncol 29(27):3669-676. doi:JCO.2011.34.9738 CrossRef
  2. Ruijter ET, Kaa CA van de, Schalken JA et al (1996) Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 180(3):295-99 CrossRef
  3. Macintosh CA, Stower M, Reid N, Maitland NJ (1998) Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Reals 58(1):23-8
  4. Stamey TA, McNeal JE, Yemoto CM et al (1999) Biological determinants of cancer progression in men with prostate cancer. Jama 281(15):1395-400 CrossRef
  5. Noguchi M, Stamey TA, McNeal JE, Nolley R (2003) Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 170(2 Pt 1):459-63 CrossRef
  6. Guo CC, Wang Y, Xiao L et al (2012) The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers. Hum Pathol 43(5):644-49 CrossRef
  7. Liu W, Laitinen S, Khan S et al (2009) Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15(5):559-65 CrossRef
  8. Eichler K, Hempel S, Wilby J et al (2006) Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 17(5):1605-612 CrossRef
  9. S3-Leitlinie_Version_2.0 Interdisziplin?re Leitlinie der Qualit?t S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms Version 2.0 -1. Aktualisierung 2011
  10. Barzell WE, Melamed MR (2007) Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate -a 4-year experience. Urology 70(6 Suppl):27-5 CrossRef
  11. Hu JC, Yu HY, Kowalczyk KJ (2011) Challenges of interpreting and improving radical prostatectomy outcomes: technique, technology, training, and tactical reporting. Eur Urol 59(6):1073-074 CrossRef
  12. Ahmed HU, Kirkham A, Arya M et al (2009) Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 6(4):197-06 CrossRef
  13. Hadaschik BA, Kuru TH, Tulea C et al (2011) A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J Urol 186(6):2214-220 CrossRef
  14. Schouten MG, Bomers JG, Yakar D et al (2012) Evaluation of a robotic technique for transrectal MRI-guided prostate biopsies. Eur Radiol 22(2):476-83 CrossRef
  15. Ahmed HU, Hindley RG, Dickinson L et al (2012) Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol (Epub ahead of print)
  16. Tatsutani K, Rubinsky B, Onik G, Dahiya R (1996) Effect of thermal variables on frozen human primary prostatic adenocarcinoma cells. Urology 48(3):441-47 CrossRef
  17. Roberts CB, Jang TL, Shao YH et al (2011) Treatment profile and complications associated with cryotherapy for localized prostate cancer: a population-based study. Prostate Cancer Prostatic Dis 14(4):313-19 CrossRef
  18. Onik G, Vaughan D, Lotenfoe R et al (2008) The ?male lumpectomy- focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol 26(5):500-505. doi:S1078-1439(08)00052-5 CrossRef
  19. Ellis DS, Manny TB, Jr, Rewcastle JC (2007) Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology 70(6 Suppl):9-5. doi:S0090-4295(07)01813-4 CrossRef
  20. Lambert EH, Bolte K, Masson P, Katz AE (2007) Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 69(6):1117-120. doi:S0090-4295(07)00289-0 CrossRef
  21. Truesdale MD, Cheetham PJ, Hruby GW et al (2010) An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: recommendations for follow up. Cancer J 16(5):544-49 CrossRef
  22. Bahn D, de Castro Abreu AL, Gill IS et al (2012) Focal Cryotherapy for Clinically Unilateral, Low-Intermediate Risk Prostate Cancer in 73 Men with a Median Follow-Up of 3.7 Years. Eur Urol. doi:S0302-2838(12)00316-8
  23. Lindner U, Weersink RA, Haider MA et al (2009) Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol 182(4):1371-377 CrossRef
  24. Moore CM, Pendse D, Emberton M (2009) Photodynamic therapy for prostate cancer--a review of current status and future promise. Nat Clin Pract Urol 6(1):18-0 CrossRef
  25. Langley S, Ahmed HU, Al-Qaisieh B et al (2012) Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int 109(Suppl 1):7-6. doi:10.1111/j.1464-410X.2011.10825.x CrossRef
  26. Ahmed HU (2009) The index lesion and the origin of prostate cancer. N Engl J Med 361(17):1704-706 CrossRef
  27. Ahmed HU, Akin O, Coleman JA et al (2012) Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int 109(11):1636-647 CrossRef
  28. Epstein JI, Allsbrook WC, Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228-242 CrossRef
  29. Xylinas E, Durand X, Campeggi A et al (2011) Pathological findings after radical prostatectomy in men eligible for active surveillance (French trial SURACAP): is the misclassification rate acceptable?. Prog Urol 21(4):264-69. doi:S1166-7087(10)00438-0 CrossRef
  30. Helpap B, K?llermann J (2012) Combined histoarchitectural and cytological biopsy grading improves grading accuracy in low-grade prostate cancer. Int J Urol 19(2):126-33 CrossRef
  
• 作者单位：Dr. D. Baumunk F.E.B.U (1)
  A. Blana (2)
  R. Ganzer (3)
  T. Henkel (4)
  J. K?llermann (5)
  A. Roosen (6)
  S. Machtens (7)
  G. Salomon (8)
  L. Sentker (9)
  U. Witzsch (10)
  K.U. K?hrmann (11)
  M. Schostak (1)
  
  1. Klinik für Urologie und Kinderurologie, Universit?tsklinikum Magdeburg A. ?. R., Leipziger Stra?e 44, 39120, Magdeburg, Deutschland
  2. Klinik für Urologie und Kinderurologie, Klinikum Fürth, Fürth, Deutschland
  3. Klinik für Urologie, Caritas-Krankenhaus St. Josef, Universit?tsklinikum Regensburg, Regensburg, Deutschland
  4. Institut für ambulante Prostatatherapien, Berlin, Deutschland
  5. Dr. Horst Schmidt Kliniken, Institut für Pathologie und Zytologie, Wiesbaden, Deutschland
  6. Urologische Klinik und Poliklinik, Klinikum der Universit?t München, Campus Gro?hadern, München, Deutschland
  7. Klinik für Urologie, Marienkrankenhaus Bergisch-Gladbach, Bergisch Gladbach, Deutschland
  8. Martini-Klinik am UKE GmbH, Hamburg, Deutschland
  9. Urologische Gemeinschaftspraxis, Sinsheim, Deutschland
  10. Klinik für Urologie und Kinderurologie, Krankenhaus Nordwest, Frankfurt am Main, Deutschland
  11. Klinik für Urologie, Theresienkrankenhaus Mannheim, Mannheim, Deutschland
  
• ISSN：1433-0563

文摘

Introduction Patients with low-risk prostate cancer (PCa) face the difficult decision between a potential overtreatment by one of the standard therapies and active surveillance (AS) with the potential insecurity regarding cancer control. A focal therapy (FT) implies a treatment of the tumor within the prostate only. Methods This review evaluates the current literature and expert opinion of different therapies suited for FT as well as concepts for prostate imaging, biopsy and histopathological evaluation. Results Currently there is a lack of multicenter, randomized, prospective data on the effectiveness of FT. Nonetheless, the published data indicate a sufficient tumor control with a favorable side effect profile. There are still flaws in the diagnostics with regard to tumor detection and histological evaluation. Multicenter studies are currently recruiting worldwide which will provide new data with a higher level of evidence. Conclusion At present, the effectiveness of FT should not be compared directly to standard radical therapies and FT should only be performed within studies. In cases of cancer progression after FT a salvage treatment should still be possible.